Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All
暂无分享,去创建一个
[1] D. Slamon. Herceptin: increasing survival in metastatic breast cancer. , 2000, European journal of oncology nursing : the official journal of European Oncology Nursing Society.
[2] R. Simon,et al. On the efficiency of targeted clinical trials , 2005, Statistics in medicine.
[3] S. Paik. Clinical trial methods to discover and validate predictive markers for treatment response in cancer. , 2003, Biotechnology annual review.
[4] D. Sargent,et al. Clinical Trial Designs for Prospective Validation of Biomarkers , 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.
[5] R. Finn,et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs , 1998, Oncogene.
[6] D. Haber,et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Peter A Kaufman,et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Elisa Rossi,et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.
[9] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[10] E. Perez,et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer , 2007 .
[11] J. Berlin,et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer , 2007, Cancer.
[12] Chan Zeng,et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Sargent,et al. Issues in clinical trial design for tumor marker studies. , 2002, Seminars in oncology.
[14] B. Conley,et al. Prognostic and Predictive Markers in Cancer , 2004, Disease markers.
[15] J. Coon,et al. Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors , 2007, Clinical Cancer Research.
[16] D. Slamon,et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. , 2004, Journal of the National Cancer Institute.
[17] S. Paik,et al. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31 , 2007 .
[18] G. Scagliotti,et al. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. , 2003, Lung cancer.
[19] D. Slamon,et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Simon,et al. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. , 2007, Journal of the National Cancer Institute.
[21] A. Ullrich,et al. Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic , 1991, Journal of Clinical Immunology.
[22] R. Simon,et al. Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials , 2004, Clinical Cancer Research.
[23] Daniel J Sargent,et al. Clinical trial designs for predictive marker validation in cancer treatment trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Marc Peeters,et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Renato Martins,et al. Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.
[26] F. Cappuzzo,et al. EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[27] M. Ostland,et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Daniel J. Freeman,et al. 3014 (Presidential session, Tue 25 Sep 12.30–14.30) ORAL Association of somatic KRAS gene mutations and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab monotherapy , 2007 .